NCT05889845: An ongoing trial by Nielsen BioSciences, Inc.
This trial is ongoing. It must report results 8 months, 2 weeks from now.
Full data
| Full entry on ClinicalTrials.gov | NCT05889845 |
|---|---|
| Title | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Candin for the Treatment of Common Warts (Verruca Vulgaris) in Adolescents and Adults |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Jan. 22, 2025 |
| Completion date | Aug. 27, 2025 |
| Required reporting date | Aug. 27, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |